ATE297466T1 - Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen - Google Patents

Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen

Info

Publication number
ATE297466T1
ATE297466T1 AT97918582T AT97918582T ATE297466T1 AT E297466 T1 ATE297466 T1 AT E297466T1 AT 97918582 T AT97918582 T AT 97918582T AT 97918582 T AT97918582 T AT 97918582T AT E297466 T1 ATE297466 T1 AT E297466T1
Authority
AT
Austria
Prior art keywords
mutants
elastase
mutant
cell migration
protein
Prior art date
Application number
AT97918582T
Other languages
English (en)
Inventor
Daniel A Lawrence
Steingrimur P Stefansson
Original Assignee
American Nat Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Nat Red Cross filed Critical American Nat Red Cross
Application granted granted Critical
Publication of ATE297466T1 publication Critical patent/ATE297466T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97918582T 1996-04-12 1997-04-11 Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen ATE297466T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1529996P 1996-04-12 1996-04-12
PCT/US1997/006071 WO1997039028A1 (en) 1996-04-12 1997-04-11 Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof

Publications (1)

Publication Number Publication Date
ATE297466T1 true ATE297466T1 (de) 2005-06-15

Family

ID=21770626

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97918582T ATE297466T1 (de) 1996-04-12 1997-04-11 Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen

Country Status (7)

Country Link
US (1) US6103498A (de)
EP (1) EP0850252B1 (de)
AT (1) ATE297466T1 (de)
AU (1) AU726406B2 (de)
CA (1) CA2233670C (de)
DE (1) DE69733462T2 (de)
WO (1) WO1997039028A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU771635B2 (en) 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2384295A1 (en) * 1999-04-28 2000-11-02 Yahia Gawad Method for determining plasminogen activator inhibitor
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
AU2001281747A1 (en) * 2000-08-02 2002-02-13 H:S Hvidovre Hospital Composition and method for the treatment or prevention of hiv infection
DE10048091A1 (de) * 2000-09-28 2002-04-25 Ernst Bayer Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
WO2003053921A2 (en) * 2001-07-18 2003-07-03 American Red Cross Mutant proteinase inhibitors and uses thereof
AU2002352115A1 (en) * 2001-11-27 2003-06-10 Bayer Aktiengesellschaft Polynucleotides encoding nexin-related serine protease inhibitor
US20060084056A1 (en) * 2002-02-13 2006-04-20 Nadia Harbeck Methods for selecting treatment regimens and predicting outcomes in cancer patients
DE60325946D1 (de) * 2002-03-04 2009-03-12 Univ Toledo Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
AU2003225592A1 (en) * 2002-03-25 2003-10-13 Molecular Innovations Method for making purified plasminogen activator-inhibitor type 1 (pai-1) and purified pai-1 made thereform
US20060121591A1 (en) * 2002-07-18 2006-06-08 American National Red Cross Mutant proteinase-inhibitors and uses thereof
US6788072B2 (en) * 2003-01-13 2004-09-07 Delphi Technologies, Inc. Apparatus and method for sensing particle accumulation in a medium
US7375076B2 (en) * 2003-05-20 2008-05-20 The Regents Of The University Of Michigan Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
US20050244893A1 (en) * 2004-04-16 2005-11-03 Wyeth Novel method for determination of plasminogen activator inhibitor
IL163453A0 (en) * 2004-08-10 2009-02-11 Yeda Res & Dev Enzyme inhibitor in leukemia
US8795730B2 (en) * 2006-01-31 2014-08-05 David John Vachon Compositions and methods for promoting the healing of tissue of multicellular organisms
AU2007238608A1 (en) 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
CA2722754A1 (en) 2007-04-27 2009-01-29 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
WO2009045412A2 (en) * 2007-10-01 2009-04-09 American Diagnostica, Inc. Methods of treatment using modified plasminogen activator inhibitor type-1 molecules
US20160199466A1 (en) * 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
JP7672641B2 (ja) 2019-09-17 2025-05-08 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
CN114867865A (zh) * 2019-11-21 2022-08-05 密执安大学评议会 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途
IL297211B2 (en) 2020-04-16 2025-12-01 Mereo Biopharma 4 Ltd Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제

Also Published As

Publication number Publication date
EP0850252A1 (de) 1998-07-01
US6103498A (en) 2000-08-15
DE69733462T2 (de) 2006-03-23
EP0850252B1 (de) 2005-06-08
CA2233670C (en) 2012-01-31
DE69733462D1 (de) 2005-07-14
EP0850252A4 (de) 2001-04-11
AU2665397A (en) 1997-11-07
WO1997039028A1 (en) 1997-10-23
CA2233670A1 (en) 1997-10-23
AU726406B2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
DE69733462D1 (de) Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen
Sottile et al. Five type I modules of fibronectin form a functional unit that binds to fibroblasts and Staphylococcus aureus
Van Damme et al. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. Chemical synthesis of MCP-2 and development of a specific RIA.
Van Deerlin et al. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
Burgess et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor
Ehrlich et al. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin.
Van den Berg et al. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells
Huang et al. Expression and purification of functional human α‐1‐antitrypsin from cultured plant cells
Stuckey et al. A model of the platelet factor 4 complex with heparin
US5401651A (en) DNA encoding ENA-78, a neutrophil activating factor
Proost et al. Human and bovine granulocyte chemotactic protein-2: complete amino acid sequence and functional characterization as chemokines
Hogg Thrombospondin 1 as an enzyme inhibitor
Kuhn et al. Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor.
Blinder et al. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
Perlmutter et al. Distinct and additive effects of elastase and endotoxin on expression of alpha 1 proteinase inhibitor in mononuclear phagocytes.
Jesmin et al. Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors
Stone et al. Localization of the heparin-binding site of glia-derived nexin/protease nexin-1 by site-directed mutagenesis
JP3226215B2 (ja) ヒト抗トロンビン３の変異体
Ocampo‐Gallego et al. Human neutrophil elastase inhibitors: Classification, biological‐synthetic sources and their relevance in related diseases
ATE421528T1 (de) Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
Owen et al. Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity
EP0724600A1 (de) Verfahren zur herstellung eines inter-alpha-trypsin inhibitor konzentrats mit therapeutischer anwendung und so erhaltenes konzentrat
AU610500B2 (en) Variants of alpha1-antitrypsin which are useful, in particular, as kallikrein inhibitors
MARUYAMA Thrombomodulin, An Endothelial Anticoagulant: Its Structure, Function and Expression: ROLES OF VASCULAR ENDOTHELIUM IN REGULATION OF CARDIOVASCULAR SYSTEM
Engelberg Endothelium in health and disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties